Dongguan Lexiang Frontline E-Commerce Co., Ltd – Trademark Portfolio

Entity Type: 16

Dongguan Lexiang Frontline E-Commerce Co., Ltd holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include SURPRIX. The owner is based in DONGGUANG, GUANGDONG.

Room 501, No. 6, Lane 2,Xin'an

DONGGUANG, GUANGDONG 523000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SURPRIX
SURPRIX
Registered 2021

Trademark Classifications

Dongguan Lexiang Frontline E-Commerce Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Dongguan Lexiang Frontline E-Commerce Co., Ltd have?

Dongguan Lexiang Frontline E-Commerce Co., Ltd has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Dongguan Lexiang Frontline E-Commerce Co., Ltd file in?

Dongguan Lexiang Frontline E-Commerce Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Dongguan Lexiang Frontline E-Commerce Co., Ltd's most well-known trademarks?

Dongguan Lexiang Frontline E-Commerce Co., Ltd's registered trademark portfolio includes well-known marks such as SURPRIX. These are among 1 currently registered trademark in the portfolio.

What is Dongguan Lexiang Frontline E-Commerce Co., Ltd's trademark registration success rate?

Dongguan Lexiang Frontline E-Commerce Co., Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.